Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
38 studies found for:    " December 15, 2010":" January 14, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Active, not recruiting A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
Condition: HIV-1 Infection
Intervention: Drug: Rilpivirine
2 Active, not recruiting Modulation of Monocyte Activation by Atorvastatin in HIV Infection
Condition: HIV Dementia
Intervention: Drug: Atorvastatin
3 Unknown  Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection
Conditions: HIV Infections;   Liver Toxicity;   Hepatitis Co-infection
Intervention:
4 Active, not recruiting
Has Results
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: Dolutegravir;   Drug: Atripla;   Drug: Abacavir/Lamivudine;   Drug: Abacavir/Lamivudine Placebo;   Drug: Dolutegravir placebo;   Drug: Atripla placebo
5 Completed Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
Condition: HIV Infection
Intervention: Biological: Fluzone®
6 Unknown  Risk Taking Behaviour in MSM and the Denial of Sexually Transmitted Diseases and HIV
Conditions: MSM;   HIV Infections;   Risky Behaviors
Intervention:
7 Withdrawn A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: GSK1349572;   Drug: GSK2248761
8 Completed Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA.
Condition: HIV Infection
Intervention: Drug: TMC278LA
9 Completed The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)
Condition: HIV Infection
Intervention: Drug: Efavirenz
10 Completed The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1
Condition: HIV Infection
Intervention: Drug: Efavirenz
11 Unknown  Ethnicity Data in HIV Positive Men Who Have Sex With Men
Condition: HIV Infections
Intervention:
12 Completed TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir
Condition: HIV Infections
Interventions: Drug: TMC278;   Drug: Raltegravir
13 Completed Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines
Condition: HIV Infections
Interventions: Biological: Adjuvanted GSK investigational HIV vaccine formulation 1;   Biological: Adjuvanted GSK investigational HIV vaccine formulation 2;   Biological: Ad35 investigational HIV vaccine;   Biological: Placebo (saline)
14 Completed Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose
Condition: HIV Infection
Interventions: Drug: Aprepitant;   Drug: Aprepitant placebo
15 Completed Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults
Condition: HIV Infections
Interventions: Biological: Profectus HIV MAG pDNA vaccine;   Biological: IL-12;   Other: Placebo
16 Completed Acquired Epidermodysplasia Verruciformis (EV) Syndrome in HIV-infected Pediatric Patients
Conditions: Flat Warts (Diagnosis);   HIV Infections
Intervention: Drug: Glycolic acid
17 Withdrawn A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: 200mg [14C]- GSK2248761
18 Withdrawn Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers.
Conditions: HIV Infections;   Healthy
Interventions: Drug: BI 224436;   Drug: Placebo
19 Completed Recovery Management Intervention in China
Conditions: Methadone;   HIV Infections
Intervention: Behavioral: Recovery management
20 Completed
Has Results
Effects of Growth Hormone Releasing Hormone in HIV
Conditions: HIV;   HIV Lipodystrophy
Interventions: Drug: tesamorelin;   Drug: placebo

   Previous Page Studies Shown (1-20) Next Page (21-38) Show next page of results    Last Page
Indicates status has not been verified in more than two years